Debioclinic

Debioclinic is a contract research organization (CRO) based in France and a subsidiary of the Swiss biopharmaceutical company Debiopharm. Specialized in clinical development, the company provides regulatory, biometric, and clinical support for drug candidates, with a strong focus on oncology and niche therapeutic areas. Debioclinic has been instrumental in the clinical progression and global registration of several significant therapies, including the blockbuster chemotherapy agent oxaliplatin (Eloxatin) and the hormone therapy triptorelin (Trelstar). As part of the synergistic Debio Group, it collaborates closely with its sister companies to bridge the gap between early-stage research and market approval. The company operates from its headquarters in Charenton-le-Pont, near Paris, and serves as the group's primary clinical arm in the European Union.